| Income statement (USD) | FY 2026 ended May 31, 2026 | FY 2025 ended May 31, 2025 | FY 2024 ended May 31, 2024 | FY 2023 ended May 31, 2023 | FY 2022 ended May 31, 2022 | FY 2021 ended May 31, 2021 |
|---|---|---|---|---|---|---|
| Revenue | 320.17M | 292.50M | 303.91M | 338.75M | 316.22M | 291.01M |
| Cost of revenue | 145.28M | 134.79M | 149.22M | 164.51M | 150.49M | 134.22M |
| Gross profit | 174.89M | 157.71M | 154.70M | 174.25M | 165.73M | 156.79M |
| Research and development | 29.45M | 26.22M | 31.51M | 29.88M | 30.74M | 36.39M |
| Operating expenses | 214.82M | 197.66M | 401.63M | 225.43M | 194.20M | 192.07M |
| Operating income | -39.93M | -39.95M | -192.44M | -51.18M | -28.47M | -35.28M |
| EBITDA | -16.97M | -14.15M | -164.72M | -20.31M | 878.0K | -9.37M |
| Interest expense | -1.61M | 2.70M | 688.0K | 861.0K | ||
| Income before tax | -36.30M | -34.03M | -191.64M | -54.44M | -29.95M | -36.05M |
| Income tax | 442.0K | -39.0K | -7.29M | -2.00M | -3.40M | -4.50M |
| Net income | -36.74M | -33.99M | -184.35M | -52.44M | -26.55M | -31.55M |
| EPS | -0.88 | -0.83 | -4.59 | -1.33 | -0.68 | -0.82 |
| EPS (diluted) | -0.88 | -0.83 | -4.59 | -1.33 | -0.68 | -0.82 |
| Diluted shares | 41.53M | 40.85M | 40.18M | 39.48M | 39.01M | 38.34M |
From Angiodynamics Inc.'s 10-K and 10-Q filings with the SEC. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read income statement or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.